GLG News by Pancreatic Cancer Oncologists in the U.S.

The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.

New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business

ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors

Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE

Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight

Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy

So, now CTLA4 blockade, touted as the next big thing in melanoma, runs into the same thing as a host of other agents with promising phase II activity: failure at the phase III level.  Pfizer's randomized phase III of tremelimumab versus the fool's gold standard dacarabzine/DTIC was...

New data with low and high dose of Avastin with Taxoter

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...

Sutent is demonstrating some activity in Lung cancer Sutent is unique in this regard versus other TKIs ? I would focus on the FELT for obvious reasons